Oculis Holding AG

NASDAQ:OCS

Biotechnology

Healthcare
$7.39 -2.43%

-$0.28 today

Market cap
$456.20M
Beta
0.13
P/E (TTM)
-5.5
EPS (TTM)
-$1.61
52W Low $10.52High $34.48

Volume 0.31M

Average 0.65M

OCS Interest Expense

Cost of servicing the company's debt during the period.

Oculis Holding AGNASDAQ: OCS

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense declines year over year

Q1 FY2026 interest expense of CHF 176.86K fell 28.4% year over year, behind the -5.0% change in trailing-twelve-month interest expense. Sequentially, it fell 26.1% from the prior quarter. Over 3 fiscal years it compounded at -50.2% a year.

Context

  • Interest expense increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -28.4% toward the trailing-twelve-month pace of -5.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CHF 176.86K-26.1% QoQ
Last fiscal yearDec 2025
CHF 795.55K+24.5% YoY
LTMMar 2026
CHF 801.45K-5.0% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-28.4%——
1 year+24.5%——
3-year CAGR-50.2%——
5-year CAGR——
10-year CAGR——

Interest Expense history

CHF · from the income statement

Latest · FY2025
795.55K CHF
Year-over-year change
+24.5%
4-year CAGR
-37.2%

Interest Expense vs competitors

How OCS compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -5.0% is the 2nd highest of 5, against a peer median of -11.6%.
  • Interest expense amounts to 159.0% of revenue for OCS, versus a peer median of 15.5%.
OCS Competitors
Interest Expense for OCS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HROWHarrow Health, Inc.LTM Mar 2026$23.13M USD-3.3%+49.4%8.6%
OCULOcular Therapeutix, Inc.LTM Mar 2026$11.63M USD-7.1%+19.0%22.3%
OKYOOKYO Pharma LimitedFY2025$883.65K USD-16.1%——
OCSOculis Holding AGLTM Mar 2026CHF 801.45K CHF-5.0%-50.2%159.0%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$313.51K USD—-42.5%94.1%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$0 USD-100.0%—0.0%
Peer median (excluding OCS) —-11.6%+19.0%15.5%

Competitors are the stored peer set for OCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000686K0
Cost of Revenue00052.08M0
Gross Profit000(51.4M)0
Gross Margin———-7492.3%—
Research & Development9.57M22.22M29.25M52.08M54.52M
Selling, General & Admin4.1M6.74M14.72M21.81M24.63M
Operating Expenses13.23M32.38M80.71M21.81M79.15M
Depreciation & Amortization235K299K287K406K521.45K
EBITDA(13.17M)(31.9M)(87.09M)(85.53M)(93.37M)
EBITDA Margin———-12468.1%—
Operating Income(13.23M)(32.38M)(80.71M)(73.2M)(79.15M)
Operating Margin———-10671.1%—
Interest Income21K126K1.59M2.17M1.69M
Interest Expense5.12M6.44M1.46M639K795.55K
Other Income / Expenses(5.29M)(6.27M)(7.98M)(12.73M)(15.54M)
Income Before Tax(18.52M)(38.64M)(88.7M)(85.94M)(94.69M)
Pre-Tax Margin———-12527.3%—
Income Tax Expense27K55K107K(160K)177.64K
Net Income(18.55M)(38.7M)(88.8M)(85.78M)(94.51M)
Net Margin———-12503.9%—
EPS (Basic)(0.57)(1.18)(2.97)(2.12)(1.81)
EPS (Diluted)(0.57)(1.18)(2.97)(2.12)(1.81)
Weighted Avg Shares32.73M32.73M29.9M40.41M52.36M
Weighted Avg Shares (Diluted)32.73M32.73M29.9M40.41M52.36M

Oculis Holding AG

NASDAQ:OCS

Intrinsic Alpha fair value

Locked

Current Price

$7.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.